Exelixis, Inc. - Common Stock (EXEL)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 28, 2026Investment Snapshot
- Trading 91% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 30.4% with 29.0% net margin
- Revenue growing at 7% annually
Exelixis, Inc. - Common Stock (EXEL) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $10.8 billion . Key value metrics: P/E ratio 16.4, P/B ratio 4.99, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Exelixis, Inc. - Common Stock — Fundamental Analysis Summary
Exelixis, Inc. - Common Stock (EXEL) is currently trading 91% above its Graham Number of $21.75, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.4x.
On financial health, EXEL shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 30.4% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.32.
StockPik's composite Value Score for EXEL is 91/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
EXEL reports a high gross margin of 96.7% (sector average: 33.5%) and a strong operating margin of 34.2%.
EXEL shows revenue growing at 7% year-over-year, with earnings growing at 50%.